40-Year-Old Woman Presents With Several Liver Nodules

Best Practices for the Medical Oncology Boards

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Final data from the phase 3 ENLIVEN trial demonstrate long-term tumor responses and a consistent safety profile with pexidartinib.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS

July 3rd 2025

Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Tislelizumab Combo Improves Outcomes in Locally Advanced ESCC Subgroups

Kristi Rosa

Novel Trispecific Antibody May Offer “Renewed Hope” in R/R Multiple Myeloma

Subgroup data from RATIONALE-306 support the frontline use of tislelizumab plus chemotherapy in locally advanced esophageal squamous cell carcinoma.

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

July 9th 2025

Pembrolizumab/Vorinostat Has Promising Activity in Squamous Cell Carcinoma

Treatment with ISB 2001 demonstrated robust responses across difficult-to-treat multiple myeloma subgroups in the phase 1 TRIgnite-1 study.

Related Content

Best Practices for the Medical Oncology Boards

Investigators of the phase 2 PEVOsq trial identify PD-L1 positivity and HPV positivity as predictive biomarkers of response to the pembrolizumab regimen.

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD

July 7th 2025

Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board exams.

Pexidartinib Elicits Sustained Benefit in Tenosynovial Giant Cell Tumors